Kezar Life Sciences, Inc. (KZR) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-05-11

Kezar Life Sciences, Inc. (KZR) has filed 11 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-11. 1 Form 8-K material event filings were reported by KZR in the last 90 days. InsiderAlpha tracks every KZR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Kezar Life Sciences, Inc. (KZR)

SEC CIK	0001645666

90-Day SEC Filing Activity

Form 4 filings (90d)	11
Form 8-K filings (90d)	1
Latest Form 4 filing	2026-05-11

Recent KZR Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-11	Chiang Pichi Luo	SVP, Corporate Controller	J — Other acquisition / disposition	2.7K	—	—	SEC
2026-05-11	Belsky Marc	Chief Financial Officer	J — Other acquisition / disposition	1.5K	—	—	SEC
2026-05-11	Belsky Marc	Chief Financial Officer	J — Other acquisition / disposition	200	—	—	SEC
2026-05-11	Schiller Mark C.	Chief Operating Officer	J — Other acquisition / disposition	2.7K	—	—	SEC
2026-05-11	Kirk Christopher J.	CEO	J — Other acquisition / disposition	43.1K	—	—	SEC
2026-05-11	Kauffman Michael	Insider	J — Other acquisition / disposition	6.4K	—	—	SEC
2026-05-11	BERGER FRANKLIN M	Insider	J — Other acquisition / disposition	89.1K	—	—	SEC
2026-05-11	Fowler John Franklin	Insider	J — Other acquisition / disposition	39.4K	—	—	SEC
2026-05-11	Fowler John Franklin	Insider	J — Other acquisition / disposition	375	—	—	SEC
2026-05-11	Fowler John Franklin	Insider	J — Other acquisition / disposition	3.8K	—	—	SEC
2025-07-02	Schiller Mark C.	Chief Operating Officer	S — Open-market sale	561	$4.28	$2K	SEC
2025-07-02	Chiang Pichi Luo	SVP, Corporate Controller	S — Open-market sale	264	$4.28	$1K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Kezar Life Sciences, Inc. (KZR). Updated in real time as new filings are submitted to the SEC.

Most-Active KZR Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Fowler John Franklin	14	—
Chiang Pichi Luo	14	—
Belsky Marc	12	—
Kirk Christopher J.	12	—
Schiller Mark C.	10	—

Recent KZR Form 8-K Material Events

2026-05-11 — Item 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 [SEC]
2026-04-03 — Item 1.02, 5.02, 9.01 · Restructuring · negative [SEC]
Kezar Life Sciences terminated its lease for approximately 48,714 square feet at its San Francisco headquarters effective April 1, 2026, paying approximately $2 million to settle remaining obligations. This lease termination, combined with an officer departure disclosed in Item 5
2026-03-30 — Item 1.01, 7.01, 9.01 · Acquisition · negative [SEC]
Kezar Life Sciences entered into a definitive merger agreement with Aurinia Pharmaceuticals, whereby Aurinia will acquire all outstanding shares of Kezar for $6.955 per share in cash plus one contingent value right (CVR) per share. The acquisition represents a takeout of the comp
2026-03-30 — Other · neutral [SEC]
Trading halt (T1) for KZR. KZR
2026-03-12 — Item 1.01, 2.01, 7.01, 9.01 · Acquisition · negative [SEC]
Kezar Life Sciences sold its Sec61-based discovery and development program assets, including the KZR-261 product candidate, to Enodia Therapeutics for $800,000 upfront plus $200,000 contingent payment and up to $127 million in milestone payments. This represents a divestiture of

Recent Insider Filings

2026-05-11 — Wallace Courtney (Insider)
2026-05-11 — Schiller Mark C. (Chief Operating Officer)
2026-05-11 — Klearman Micki (Insider)
2026-05-11 — Kirk Christopher J. (CEO)
2026-05-11 — Kauffman Michael (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in KZR insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

KZR Insider Trading — FAQ

What is the latest insider trade for KZR?: Kezar Life Sciences, Inc. (KZR) had 11 insider filings in the last 90 days, with the most recent on 2026-05-11. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying KZR stock?: 0 insider purchases of KZR were filed in the last 90 days.
How many insiders are selling KZR stock?: 0 insider sales of KZR were filed in the last 90 days.
Where can I see KZR SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every KZR SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live KZR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.